• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Stanislav Polovets

    3/12/21 4:28:05 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care
    Get the next $ANCN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Polovets Stanislav

    (Last) (First) (Middle)
    ONE KENDALL SQUARE, BUILDING 1400E
    SUITE 14-105

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Anchiano Therapeutics Ltd. [ ANCN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/23/2020
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.17 07/16/2020 A 55,000 (1) 07/15/2030 Ordinary Shares 55,000 $0.00 55,000 D
    Explanation of Responses:
    1. 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter.
    Remarks:
    /s/ Jason Minio, Attorney-in-Fact 03/12/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANCN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANCN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Ltd. Gp Israel Orbimed was granted 288,170 units of American Depository Shares

    4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    3/18/21 9:59:48 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    SEC Form 4: Peter Thiel bought $0 worth of American Depositary Shares (230,536 units at $0.00)

    4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    3/18/21 9:42:28 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    SEC Form 3: Peter Thiel claimed ownership of 877,973 units of American Depositary Shares

    3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

    3/18/21 9:41:46 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    $ANCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ANCN
    SEC Filings

    View All

    Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

    Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that Anchiano’s shareholders voted to approve the contemplated merger with Chemomab and the issuance of AnchianoAmerican Depositary Shares (ADSs) in conn

    3/15/21 5:54:21 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

    Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis

    12/15/20 9:00:00 AM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K/A filed by Anchiano Therapeutics Ltd.

    8-K/A - Chemomab Therapeutics Ltd. (0001534248) (Filer)

    3/19/21 8:51:44 AM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    SEC Form 10-K filed

    10-K - Anchiano Therapeutics Ltd. (0001534248) (Filer)

    3/9/21 4:27:54 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care

    SEC Form 425 filed

    425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)

    3/9/21 1:00:08 PM ET
    $ANCN
    Major Pharmaceuticals
    Health Care